EFdA-TP

• UNSPSC Description:

  EFdA-TP is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP inhibits HIV-1 RT with multiple mechanisms[1].

• Target Antigen:

  DNA/RNA Synthesis; HIV; Reverse Transcriptase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/efda-tp.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=[P](O[P](O[P](O)(O)=O)(O)=O)(O)OC[C@]1(O[C@@](C[C@@H]1O)([H])N2C3=NC(F)=NC(N)=C3N=C2)C#C

• Molecular Weight:

  533.19

• References & Citations:

  [1]Eleftherios Michailidis, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289(35):24533-48.|[2]Martin Markowitz, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. Curr Opin HIV AIDS. 2018 Jul;13(4):294-299.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  950913-56-1